Please Wait
Applying Filters...
menu
    • menu
    FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024

    Data Compilation
    #PharmaFlow

    Pipeline Prospector 2024 highlights: Rise in new breed of biotechs with maiden approvals; GLP-1 meds show promise beyond obesity

    Stock Recap
    #PipelineProspector

    Menu

    pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 234Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    30/12/2024 Dr. Reddy's Laboratories
    India
    		 DR. REDDY'S LABORATORIES LIMITED Hyderabad IN R1-CEP 2014-109 - Rev 02 Capecitabine 2022-09-13 Valid Chemical 2762
    30/12/2024 Granules India Limited
    India
    		 GRANULES INDIA LIMITED Hyderabad IN CEP 2019-091 - Rev 01 Capecitabine 2024-06-06 Valid Chemical 2762